Merck & Co. Aktie News

Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.

Intuitive Surgical just put up a strong quarter, reminding Wall Street that it is a growth stock. Merck is a drug giant with a yield near the highest levels of the past decade and a reasonable payout ratio.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg. WINREVAIR, an activin signaling inhibitor, is now FDA-approved for the treatment of adu...

DaVita's recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.

Merck & Co., Inc. faces a pivotal Q3 earnings report as Keytruda's patent expiration looms and pipeline diversification efforts accelerate. MRK's oncology pipeline, including Keytruda Qlex and multiple ADCs, aims to offset future revenue loss, but execution risk remains high. Non-oncology segments face setbacks, with Gardasil sales declining and new launches like Winrevair underperforming expec...

Income investors rarely chase the loudest headlines.

BOSTON , Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operati...

Slow and steady performers do better over the long term.